Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03200860 Not yet recruiting - Clinical trials for Heart Failure,Congestive

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure

EMPA-RESPONSE
Start date: December 2017
Phase: Phase 2
Study type: Interventional

Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide. Short term mortality and rehospitalization are extremely high (20-30% within 3-6 months) and there is no therapy available that improves clinical outcome in these patients. Empagliflozin is a selective inhibitor of sodium glucose co-transporter with diuretic and renal- protective properties. In patients with type 2 diabetes at high risk for cardiovascular events, empagliflozin reduced the risk of hospitalization for heart failure by 35%. Based on the promising pharmacological profile of empagliflozin in relation to the needs for treatment of acute decompensated heart failure, we hypothesize that empagliflozin exerts positive effects in acute decompensated heart failure, with or without diabetes, This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.

NCT ID: NCT03198585 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Empire HF
Start date: June 2017
Phase: Phase 2
Study type: Interventional

To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction. The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).

NCT ID: NCT03195660 Not yet recruiting - Sleep Apnea Clinical Trials

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

CAT-PEF
Start date: June 2017
Phase: N/A
Study type: Interventional

This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.

NCT ID: NCT03193801 Not yet recruiting - Heart Failure Clinical Trials

PARTNER 3 Trial - Mitral Valve in Valve

Start date: August 2017
Phase: N/A
Study type: Interventional

To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

NCT ID: NCT03191656 Not yet recruiting - Heart Failure Clinical Trials

REDUCE LAP-HF III Corvia Protocol 1701

REDUCELAPHFIII
Start date: July 4, 2017
Phase: N/A
Study type: Observational

This is a post market trial to be conducted at several sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System II, to further evaluate efficacy, safety and quality of life outcomes as a new treatment for patients with heart failure in a "real world" practice setting.

NCT ID: NCT03189901 Not yet recruiting - Acute Heart Failure Clinical Trials

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

EMSAHF
Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to use levosimendan may reduces the risk of heart failure and improve the outcome.

NCT ID: NCT03189654 Not yet recruiting - Heart Failure Clinical Trials

Noninvasive Ventilation Therapy for the Treatment of Pleural Effusion in Patients With Heart Failure

Start date: June 2017
Phase: N/A
Study type: Observational [Patient Registry]

There are no investigations so far whether an application of positive pressure during non-invasive ventilation might be a therapeutic option for transudative pleural effusion in patients with heart failure. In view of the pathophysiological process with pleural effusion resulting from an increase in intravascular hydrostatic pressure, non-invasive ventilation might provide an improvement. The aim of the present study is to investigate whether an additional non-invasive ventilation therapy leads to an improved suppression of pleural effusion in heart failure patients.

NCT ID: NCT03189368 Not yet recruiting - Heart Failure Clinical Trials

Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling

HUMVEE
Start date: July 1, 2017
Phase: N/A
Study type: Observational

To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart

NCT ID: NCT03187509 Not yet recruiting - Heart Failure Clinical Trials

Weight-Based Torsemide Dosing in Subjects With Heart Failure

Start date: July 2017
Phase: N/A
Study type: Interventional

This study will be a randomized open-label pilot study. The purpose of the study is to compare standard of care outpatient heart failure management versus a weight based torsemide regimen. Subjects admitted to the hospital for heart failure exacerbation will be randomized upon discharge to either standard of care outpatient heart failure management or a weight based torsemide regimen. Those subjects randomized to standard of care therapy will be prescribed a daily fixed dose of a loop diuretic at hospital discharge and have a follow-up appointment within one week of discharge. All management decisions including loop diuretic type, dose and frequency will be made at the discretion of the subject's personal physician. Those randomized to an individualized weight based torsemide regimen will be prescribed a dose of torsemide upon hospital discharge based on a prespecified algorithm. These subjects will then undergo physician-subject phone encounters three times a week where the subject's torsemide dose will be modified based on the prespecified algorithm which incorporates current symptoms and weight. Primary end-point will be an unbiased estimate of 30-day all cause readmission rates. Secondary end-points include incidence of acute kidney injury, changes in brain natriuretic peptide levels from baseline and a preliminary estimate of the effect size and feasibility of a weight-based torsemide regimen intervention in order to plan a future larger study.

NCT ID: NCT03186404 Not yet recruiting - Cancer Clinical Trials

Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study

SPARE-HF
Start date: July 2017
Phase: Phase 2
Study type: Interventional

Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF). Current standard of care for preventing AC induced HF (AIHF) is cardiac surveillance followed by initiation of treatment once HF is diagnosed. With this approach 89% of patients fail to recover heart function and 46% will experience adverse cardiac events. Therefore there is a need for effective preventive therapy to reduce the risk of AIHF. Based on small human studies, animal studies, and our own pilot data, statins are an ideal class of drug for this purpose. We will conduct a pilot double blinded, placebo controlled, randomized controlled trial to assess whether pre-treatment with statins before AC can prevent heart dysfunction. Eligible patients with cardiovascular risk factors scheduled to receive AC will be recruited. They will be randomized to statin therapy or placebo and followed until the end of cancer treatment. Primary outcome is the difference in cardiac MRI-determined left ventricular ejection fraction between pre-AC and end of treatment.